Hypertension / Heart Failure
Vitamin D deficiency associated with proinflammatory status in elderly hypertensives
4-3-2014 • Laird et al., J Clin Endocrinol Metab 2014
Negative associations were seen between vitamin D and pro-inflammatory cytokines, and a more pro-inflammatory IL-6 to IL-10 ratio was more often seen in vitamin D deficient individuals.
Pro-inflammatory cytokines associated with incident CHD outcomes
4-3-2014 • Kaptoge et al. Eur Heart J 2014
IL-6, IL-18 and TNF-α were positively associated with incident MI or CHD death risk, independently of many other common CV risk factors, thereby supporting the inflammation hypothesis of vascular disease.
News • 3-3-2014
FDA and EMA say incretin-based antidiabetics do not cause pancreatitis and pancreatic cancer
Both agencies independently undertook comprehensive evaluations of pancreatic safety of these agents, and conclude that recent concerns are inconsistent with the current data.
Increased incidence of major CV events after death of partner
26-2-2014 • Carey IM et al., JAMA Intern Med. 2014
Large primary care database study showed a marked increase in the incidence of MI, stroke, ACS and PE in the months after the death of the partner.
Vegetarian diet associated with lower blood pressure
25-2-2014 • Yokoyama Y et al., JAMA Intern Med. 2014
Meta-analysis of both clinical trials and observational studies show that consumption of vegetarian diets is associated with lower systolic and diastolic blood pressure.
Daily AF burden is associated with increased risk of ischaemic stroke or TIA
24-2-2014 • Boriani G et al.Eur Heart J 2014
Measuring burden of atrial fibrillation with implanted device may be clinically relevant, and specific thresholds of daily AF burden may identify a substantial increase in the risk of ischaemic stroke.
Potential therapeutic target to inhibit thrombogenesis without affecting haemostasis
20-2-2014 • Tilly et al., Cardiovasc Res. 2014
Murine and human studies demonstrate that specific inhibition of the prostaglandin E2 receptor EP3 function may serve as therapeutic target to inhibit platelet function without increasing bleeding.
Snapshot 2013 Prof. Ulf Landmesser (University Hospital Zurich, CH) provides an overview of the targets for intervention in the inflammatory process in cardiovascular disease.
Prof. Magnus Simren, Gotheborg, Sweden provides an update on new drug treatments for chronic constipation
Dr. Bob Giugliano, discusses the results and implications of the recently published ENGAGE trial which evaluated edoxaban, the most recent Factor Xa inhibitor.
Snapshot 2013 Prof. Bryan Brewer (Washington DC, USA) discusses the options left for HDL therapies to reduce the residual risk in statin therapy. What are the HDL therapies in active investigation?
Increased risk of stroke in women but not men with high HbA1c
26-2-2014 • Zhao et al, Diabetologia 2014
HbA1c is positively associated with risk of stroke in female patients with type 2 diabetes, particularly when over 55 years of age, irrespective of use of glucose-lowering medication and race.
News • 26-2-2014
Once-weekly dulaglutide non-inferior to once-daily liraglutide in reduction of HbA1c
AWARD-6 study shows that long-acting glucagon-like peptide 1 receptor agonist dulaglutide may be an important new treatment option for type 2 diabetes.
Sitagliptin generally well tolerated in elderly patients with type 2 diabetes
25-2-2014 • Round EM et al. Drugs Aging. 2014
Pooled analysis of clinical trials shows that T2DM patients of over 65 years taking DPP-4 inhibitor sitagliptin showed few adverse events and a low incidence of hypoglycaemia.
Higher consumption of sugar-sweetened beverages associated with hypertension
20-2-2014 • Malik et al., Am J Cardiol, 2014
Systematic review suggests that intake of over 1 serving per day is associated with an increased risk of developing hypertension.
Adding sitagliptin effective in T2DM, irrespective of insulin regime
19-2-2014 • Takai M. Diabetes Res Clin Pract. 2014
Retrospective multicenter study confirms that combination therapy of sitagliptin and intensive insulin therapy stably lowers HbA1c in type 2 diabetes patients with poor glycaemic control.
Cardio Diabetes Master Class, Asian chapter
12-4-2014, Almaty, Kazachstan
Lipid Master Class
SNAPSHOT meeting 2014
30-8-2014, Barcelona, Spain
All upcoming meetings...
Meeting reports & resources
CV Risk Master Class Latin American chapter
Bogota, Colombia, November 1- 2, 2013
Inflammation & cardiovascular disease: Exploring new options for intervention
ESC Amsterdam, September 2, 2012
PCSK9: the new lipid target in preventive cardiology?
ESC Amsterdam, August 31, 2013
SNAPSHOT meeting: Novel interventions in CVD: Controversies & hot issues
All meeting reports...
Statin-loaded HDL nanoparticle
CV Risk Master Class Latin American chapter
Applying new insights to clinical practice
The challenge for CV Risk management in Latin America:
Opportunities for early intervention
Nanotechnology: new in cardiovascular medicine